clinical usefulness of somatostatin receptor scintigraphy in the diagnosis of neuroendocrine neoplasms

Objective(s): we investigated the detectability of somatostatin receptor scintigraphy (srs) for neuroendocrine neoplasms (nen).methods: from january 2016 to october 2020, 125 srs examinations using indium-111 pentetreotide performed for patients with nen lesions were retrospectively evaluated. the detection rate of nen lesions was determined according to histopathological classification by primary site and by organ.results: at least one nen lesion was detected in 73% (91/125) with a positive krenning score of ≥2 in srs. the detection of abdominal nens (gastrointestinal tract, 38; pancreas, 62; and others, 14) was 89% (49/55) for neuroendocrine tumor (net)-grade (g) 1, 78% (32/41) for net-g2, 66% (2/3) for net-g3, 31% (4/13) for neuroendocrine carcinoma (nec), 100% (1/1) for mixed neuroendocrine–non-neuroendocrine neoplasm, and 0% (0/1) for non-classified nen. that of thoracic nens was 33% (2/6) for typical carcinoid tumor and 40% (2/5) for atypical carcinoid tumor. for a total of 226 organ lesions, hepatic lesions were 76% (58/76); pancreatic lesions, 61% (31/51); lymph node lesions, 77% (27/35); bone lesions, 83% (20/24); duodenal lesions, 82% (9/11); and other lesions, 41% (11/27).conclusion: the detectability of srs for nen in japan was verified at a center, and its usefulness was confirmed.